Swiss drugmaker Roche has enter a deal worth up to $555 million to work with India’s Curadev Pharma on new cancer immunotherapies. The companies have entered into a research collaboration and exclusive license agreement for the development and commercialization of IDO1 and TDO inhibitors. The deal covers the development of …